Introduction {#dmw017s6}
============

Subfertility, defined as a failure to achieve a clinical pregnancy after at least 12 months of regular unprotected coitus ([@dmw017C158]), affects \~15% of all couples. In \~17% of these couples, a severe male factor, defined as a total motile sperm count below 3 × 10^6^, is present ([@dmw017C139]). A severe male factor may present as azoospermia (complete absence of spermatozoa in the ejaculate) or oligozoospermia (low number of spermatozoa in the ejaculate). In case of a severe male factor, a patient's own biological children can be generated by ICSI with either ejaculated spermatozoa (in case of oligozoospermia) or surgically retrieved testicular spermatozoa by means of testicular sperm extraction (TESE) (in case of azoospermia). Currently, no direct clinical treatment exists for a severe male factor.

A severe male factor is typically caused by a disturbance during spermatogenesis. Spermatogenesis occurs in the seminiferous tubules inside the testis. Essential to this process are spermatogonial stem cells (SSCs) that maintain a perfect balance between self-renewal and differentiation into mature sperm, thereby sustaining fertility throughout a man's life. Both oligozoospermia and azoospermia can be due to a reduction in SSC numbers throughout the testis as seen in testicular biopsies taken from these men ([@dmw017C131]; [@dmw017C153]; [@dmw017C43]). In some of these men, the testicular biopsies display focal spermatogenesis, where sperm is only produced in a subset of seminiferous tubules. Although the production of spermatozoa is limited due to the low number of SSCs, the existing SSCs are still functional and capable of continuous self-renewal and differentiation ([@dmw017C126]).

While the etiology of a severe male factor remains largely unknown, a few genetic defects ([@dmw017C142]; [@dmw017C134]; [@dmw017C70]), including structural and numerical chromosomal abnormalities ([@dmw017C18]; [@dmw017C96]) and Y-chromosome deletions ([@dmw017C74]; [@dmw017C95]), have been identified to associate with a severe male factor-induced subfertility. In addition, male subfertility can be attributed to previous gonadotoxic treatment ([@dmw017C86]). Both chemotherapy and radiotherapy are known to destroy the SSC pool, resulting in oligozoospermia or azoospermia in a large proportion of cancer survivors ([@dmw017C50]).

A possible future application that could directly treat a severe male factor might be autotransplantation of SSCs. Transplantation of SSCs that are stored prior to cancer treatment is proposed as a means to restore fertility in childhood cancer survivors. This application involves transplantation of SSCs into the seminiferous tubules via the efferent duct or rete testis ([@dmw017C8]; [@dmw017C20]). Upon SSC transplantation (SSCT), SSCs migrate to the basement membrane of recipient seminiferous tubules, colonize the epithelium and undergo self-renewal and differentiation so that permanent spermatogenesis is established. Therefore, SSCT should allow natural conception without further fertility treatment, making SSCT a direct treatment for a severe male factor.

In case the severe male factor is due to a genomic mutation, SSCT can only be successful if it is combined with correction of the mutation. Recent advances in genomic editing, especially those with the clustered regulatory interspaced short palindromic repeats-associated protein 9 (CRIPSR-Cas9) system, can allow for rapid, easy and highly efficient genetic alterations of a wide array of cell types and organisms including human cells ([@dmw017C117]). Thus, if genomic editing is combined with SSCT, it would in principle allow those suffering from spermatogenic failure to have their own biological children. Furthermore, SSCT with genomic editing may be used to prevent paternal transmission of genomic diseases.

In this review, the clinical prospects of SSCT with or without genomic editing for male adult cancer survivors, for men with oligozoospermia and azoospermia and for carriers of genomic diseases are discussed (Fig. [1](#dmw017F1){ref-type="fig"}). Figure 1A schematic depiction of the proposed SSCT therapy. (**a**) A testicular biopsy is taken from the patient and cryopreserved. From the biopsy, SSCs are propagated *in vitro,* during which endogenous genomic defects may be repaired. Propagated SSCs are subsequently autotransplanted to the testis and then colonize the testis and restore spermatogenesis, enabling the patient to father a child without additional therapy. (**b**) The testicular histology of men with a severe male factor in different patient groups. The histology may show various phenotypes throughout the testis. For male (childhood) cancer survivors, a biopsy is cryopreserved prior to cancer therapy. Hence, thawing of the cryopreserved biopsy is indispensable to the treatment. *In vitro* propagation is needed for all patient groups, while genomic modification is only needed for those with a maturation arrest or carriers of diseases. In male carriers of diseases with full spermatogenesis, all germ cells including spermatids express the mutated genes, and local irradiation of the testis is required prior to transplantation to remove the mutated endogenous spermatids. After (genomically modified) SSCT, testis histology should, in theory, restore to full spermatogenesis.

Methods {#dmw017s7}
=======

We performed a narrative review using the literature available on PubMed not restricted to any publishing year on topics of subfertility, fertility treatments, (molecular regulation of) spermatogenesis and SSCT, inherited (genetic) disorders, prenatal screening methods, genomic editing and germline editing. For germline editing, we focussed on the novel clustered regulatory interspaced short palindromic repeats-associated protein 9 (CRISPR-Cas9) system. We included papers written in English only.

Clinical prospects of SSCT to restore spermatogenesis {#dmw017s8}
=====================================================

The first successful SSCT was reported in 1994 and resulted in fertility restoration in sterile recipient mice upon transplantation of donor-derived SSCs ([@dmw017C9]). Subsequent studies substantiated the findings by showing restoration of spermatogenesis after SSCT in mice ([@dmw017C60]; [@dmw017C31]; [@dmw017C72]; [@dmw017C157]; [@dmw017C146]) and other animal models ([@dmw017C49]; [@dmw017C53]; [@dmw017C112]; [@dmw017C94]; [@dmw017C63]), including non-human primates ([@dmw017C122]; [@dmw017C45]). In mice, SSCs can be transplanted into the recipient seminiferous tubules by injecting the efferent ducts, the rete testis or directly injecting seminiferous tubules ([@dmw017C97]). Injection via the efferent ducts is mostly employed in rodents ([@dmw017C30]). Yet, due to the anatomic and size difference in testes, ultrasound-guided transplantation via the intra-rete testis has been proved to be the least invasive and most efficient and successful protocol for non-rodent species such as pigs ([@dmw017C49]), bulls ([@dmw017C53]), primates ([@dmw017C122]; [@dmw017C120]; [@dmw017C45]) and *ex vivo* human testes ([@dmw017C122]; [@dmw017C92]). Crucial to this procedure is the injection of cells via the rete testis, and optimization is needed in this respect to augment success rates ([@dmw017C55]). In addition, the quality and quantity of SSC niches in the recipient testis makes a difference to the success of autologous transplantation ([@dmw017C56]). To date, multiple papers describe the generation of SSCT-induced healthy offspring in rodents ([@dmw017C31]; [@dmw017C157]; [@dmw017C77]; [@dmw017C72]; [@dmw017C32]; [@dmw017C146]) and non-rodent large animal models such as goats and sheep ([@dmw017C48]; [@dmw017C46]; [@dmw017C162]). A breakthrough was recently achieved by [@dmw017C45], who successfully performed autologous and allogeneic transplantation of SSCs from rhesus monkey, leading to the generation of donor-derived sperm in both cases. Subsequently, ICSI was conducted to fertilize oocytes, and embryos with donor paternal origin were finally produced. This demonstration in primates provides prospects for future clinical translation of SSCT.

For humans, SSCT has been proposed as a future clinical application for those men with the risk of complete germ cell depletion that have no option to cryopreserve sperm, in particular, prepubertal cancer patients ([@dmw017C8]; [@dmw017C33]; [@dmw017C129]; [@dmw017C114]) and, theoretically, even in case of focal spermatogenesis ([@dmw017C90]). Prepubertal cancer patients especially rely on SSCT because spermatogenesis is not initiated yet, which means that semen cryopreservation prior to treatment is not an option. By opting for storage of a testicular biopsy before cancer therapy, SSCT can be applied later in life when the patient is cured and expresses the wish to have children ([@dmw017C129]; [@dmw017C103]). In this case, cryopreservation of biopsied testicular tissues constitutes an important part of fertility preservation ([@dmw017C121]). Currently the most popular avenue to preserve pieces of testicular tissues is through controlled slow freezing ([@dmw017C66], [@dmw017C65]; [@dmw017C149], [@dmw017C150]; [@dmw017C26]; [@dmw017C29]), with the addition of cryoprotective agents such as dimethyl sulphoxide or ethylene glycol with or without sucrose ([@dmw017C66], [@dmw017C65]; [@dmw017C75]; [@dmw017C149], [@dmw017C151]; [@dmw017C104]; [@dmw017C103]). Vitrification instead of controlled slow freezing has also been tested with positive outcomes ([@dmw017C13]; [@dmw017C4]; [@dmw017C105]). Nevertheless, protocols for tissue preservation require further optimization to maximize the viability of post-thawed human testicular tissues ([@dmw017C103]).

Following successful cryopreservation, conventional SSCT can be performed at a later stage, which involves the transplantation of the patient's SSCs into one's own testis (i.e. autotransplantation). After autotransplantation, SSCs migrate to the basement membrane of the recipient seminiferous epithelium, from where they reinitiate spermatogenesis (Fig. [1](#dmw017F1){ref-type="fig"}). In this way, the patient can (re)gain his fertility and generate their own biological children by natural conception, as shown in animal experiments ([@dmw017C48]; [@dmw017C31]).

The efficiency of SSCT is highly dependent on the number of transplanted SSCs ([@dmw017C19]; [@dmw017C88]). Previous reports suggest that SSCT is unlikely to become clinically applicable without an approach to successfully expanding human SSCs *in vitro* ([@dmw017C56], [@dmw017C54]). *In vitro* expansion of SSCs has been successfully demonstrated in studies using rodent SSCs [@dmw017C60], [@dmw017C61], [@dmw017C59]; [@dmw017C71]; [@dmw017C111]). Even after 2 years of culture, the SSCs retained the capacity to colonize the basal membrane of seminiferous tubules and could further develop into healthy and functional sperm ([@dmw017C61]). In human trials, SSCs can first be isolated from biopsies and then subjected to primary culture to increase their number for the sake of SSCT. Several culture systems have been established for human adult SSCs ([@dmw017C116]; [@dmw017C80]; [@dmw017C69]; [@dmw017C1]; [@dmw017C34]), as well as for human prepubertal SSCs ([@dmw017C113]). Presently (xeno)transplantation is the well-acknowledged and only available assay for functionality of human SSCs. It is shown that *in vitro* propagated human SSCs are capable of migrating to the niche at the basal membrane of the seminiferous tubules upon xenotransplantation into the testis of immunodeficient mice ([@dmw017C116], [@dmw017C113]), indicating that these cultured testicular cells still have SSC capabilities. Nevertheless, human spermatogenesis is not initiated in the mouse model. This is not unexpected given the large phylogenetic distance between mice and humans, and because of this, the murine niche cannot support full development of human SSCs into sperm ([@dmw017C89]). Despite that, by comparing the numbers of migrated SSCs in the recipient testis after xenotransplantation of early and late passages from primary human testicular cultures, it has been established that adult as well as prepubertal SSCs can indeed proliferate in culture ([@dmw017C116], [@dmw017C113]). Thus, the successful expansion of human SSCs in culture paves the way for clinical applications of SSCT.

Once SSCT is clinically implemented for childhood cancer survivors, other patient groups that have the risk of becoming subfertile or that suffer from subfertility might also benefit from this treatment. In a recent study in azoospermic men, it was shown that these men hold a positive attitude toward SSCT, which was persistent even after acknowledging that a new experimental technique might have some risks for themselves or their offspring ([@dmw017C42]).

SSCT to restore fertility in adult cancer survivors {#dmw017s8a}
---------------------------------------------------

Due to the high sensitivity of spermatogonia to DNA damage ([@dmw017C138]; [@dmw017C86]), spermatogonial apoptosis and subsequent subfertility is a major side-effect of most cancer treatments. The chance of becoming azoospermic temporarily or permanently after cancer therapy is highly dependent on the type and dosage of the treatment ([@dmw017C50]). A recent study has shown that 25% of patients who underwent chemotherapy were azoospermic after 7--218 months (median: 40 months), with the highest chance of azoospermia in Hodgkin disease survivors (63%) ([@dmw017C133]).

Cryopreservation of semen prior to treatment is historically an effective and inexpensive way to preserve fertility in adult male cancer patients. The cryopreserved semen can be used to achieve a pregnancy by cervical or intrauterine insemination (IUI) or, in case the quality of the semen is too low, by IVF or ICSI treatment. However, cancer patients often show decreased fertility at the time of cancer diagnosis. In fact, [@dmw017C109] report that 12% of patients who wish to store their semen are azoospermic at the time of cancer diagnosis. Moreover, semen cryopreservation severely reduces sperm motility ([@dmw017C64]; [@dmw017C7]), sperm count ([@dmw017C64]) and DNA integrity ([@dmw017C137]). Hampered sperm motility significantly decreases the chance of live birth after IUI ([@dmw017C41]), and therefore the majority of patients who make use of cryopreserved spermatozoa have to resort to IVF/ICSI. However, IVF/ICSI is costly and burdensome, and requires ovarian hyperstimulation of the healthy female to retrieve oocytes, which is not risk-free and leads to onset of the ovarian hyperstimulation syndrome in 1--8% of stimulated women ([@dmw017C85]; [@dmw017C28]). In addition, it is well known that IVF/ICSI is associated with adverse short-term outcomes including preterm birth, lower birthweight and a higher prevalence of birth defects ([@dmw017C40]; [@dmw017C37]).

Although SSCT does require a testis biopsy and treatment of the affected male, it would avoid IVF/ICSI treatment of the healthy female partner since natural conception might be feasible after SSCT. In the future, SSCT may therefore become an appealing alternative for fertility preservation in adult cancer patients in a similar way as described for prepubertal cancer patients by cryopreserving a testis biopsy before onset of cancer treatment.

SSCT to enhance fertility in oligozoospermic and azoospermic men {#dmw017s8b}
----------------------------------------------------------------

Oligozoospermic and azoospermic men are capable of fertilization if they produce morphologically normal sperm in the testis. In couples where the male is oligozoospermic or azoospermic, ICSI is used to achieve fertilization with ejaculated or surgically retrieved spermatozoa, respectively. However, since oligozoospermia and azoospermia may be caused by a reduction in functional SSCs ([@dmw017C131]; [@dmw017C153]; [@dmw017C43]), a simple increase in SSCs may restore spermatogenesis and fertility in these men. This is especially relevant to the patients who display focal spermatogenesis at the histological level, in which some tubules show normal spermatogenesis, while others display Sertoli cell-only syndrome. The tubules with normal spermatogenesis harbor functional SSCs, and the hypothesis is that if these spermatogonia are propagated *in vitro* and transplanted back into the testis, they will repopulate the empty tubules and initiate spermatogenesis in these tubules. A recent article describes the characteristics of cultured SSCs deriving from patients who suffer from focal spermatogenesis due to a deletion of the azoospermia factor c (*AZFc)* region on the Y chromosome ([@dmw017C90]). *In vitro* propagated SSCs from these men with focal spermatogenesis behaved similarly during culture and showed comparable gene expression of key spermatogonial markers when compared to SSCs originating from healthy counterparts with normal spermatogenesis. These results suggest that patients with oligozoospermia or azoospermia as a result of focal spermatogenesis might also benefit from propagation and transplantation of their own SSCs. Yet, this hypothesis needs to be demonstrated in clinical trials. However, one drawback that should be accounted for is that if a mutation is present on the Y chromosome, as in the case of men with *AZFc* deletions, male offspring of these men will harbor the same mutation and are likely to be oligozoospermic or azoospermic too ([@dmw017C99]). It makes sense that this also holds true for mutations on other chromosomes. However, this problem also arises with other contemporary fertility treatment, such as IVF/ICSI with or without TESE. In order to prevent transmission of these genetic aberrations, additional measures have to be taken.

Clinical prospects of SSCT and germline genomic editing {#dmw017s9}
=======================================================

While the use of SSCT for adult cancer patients or oligozoospermic and azoospermic patients that display focal spermatogenesis seems rather straightforward, azoospermic patients suffering from a maturation arrest in spermatogenesis cannot directly benefit from SSCT because transplantation of the patient's SSCs would result in the same arrested phenotype and not cure their spermatogenic failure (Fig. [1](#dmw017F1){ref-type="fig"}). However, in some cases, the maturation arrest may be attributed to genetic mutations or arises from epigenetic disturbances. Repair of these disorders in SSCs before SSCT would theoretically restore spermatogenesis and subsequent fertility in these patients and in addition prevent the transmission of the mutation to the offspring. The fact that human SSCs can propagate in culture for extended periods of time enables (epi)genetic editing prior to transplantation.

With recent advances in the field of genomic editing, in particular the use of novel techniques such as the CRISPR-Cas9 system, SSCT with genetically modified SSCs has become feasible ([@dmw017C22]; [@dmw017C148]; [@dmw017C11]; [@dmw017C119]). In addition, recent work has shown that epigenetic editing is also possible with CRIPSR-Cas9 ([@dmw017C47]).

CRISPR-Cas9 to genomically modify SSCs {#dmw017s9a}
--------------------------------------

Traditional genome editing mainly relies on homologous recombination in embryonic stem cells (ESCs). Over the last decade, novel genome editing platforms such as zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and most recently the CRISPR-Cas9 system have been developed. These techniques are based on engineered nucleases that can cause a double-strand break of DNA, and are much less laborious and time-consuming compared to traditional strategies. With the emergence of these novel techniques (Table [1](#dmw017TB1){ref-type="table"}), the majority of cell types, including SSCs, can now be targeted. Table IAn overview of different genome editing techniques.Genome editing systemsHomologous recombination without engineered nucleasesConventional engineered nucleases (ZFNs/TALENs)Novel engineered nucleases (CRISPR-Cas9)Novel engineered nucleases (GeCKO^[a](#dmw017tfn1){ref-type="table-fn"}^)Target cellsMostly ESCsMost cell typesMost cell typesMost cell typesApproaches to delivering targeting vectorsNon-viral transfection/viral transduction/microinjectionNon-viral transfection/viral transduction/microinjectionNon-viral transfection/viral transduction/microinjectionLentiviral transductionTechnical difficultyHighHighLowIntermediateTargeting efficiencyLowVariableGenerally highHighOff-target effectsLowVariableGenerally lowVariablePossible to target a large scale of genes in parallel?NoNoNoYesSuitable for the clinic?No, due to low efficiency and the typical requirement of ESCsNot optimalYesCurrently not due to lentiviral transduction[^2]

Prior to clinical application of genomically modified SSCs, the safety of the patient needs to be guaranteed. In a clinical setting, off-target effects are not acceptable, and technical simplicity would be desirable. ZFNs and TALENs were utilized to successfully manipulate mouse SSCs ([@dmw017C22]). However, the required design and engineering of nucleases necessary for both ZFNs and TALENs is strenuous and of high technical difficulty. A better alternative to genetically modify SSCs seems to be the unprecedentedly simple CRISPR-Cas9 system (Fig. [2](#dmw017F2){ref-type="fig"}), and articles describing successful manipulation of rodent SSCs by way of CRISPR are now available ([@dmw017C148]; [@dmw017C11]; [@dmw017C119]). The CRISPR-Cas9 system not only bypasses the engineering of nucleases but also generates far less off-target effects compared with ZFNs ([@dmw017C135]). According to a recent report, with genome-wide screens, no obvious off-target genetic or epigenetic changes could be detected in a large SSCT experiment involving CRISPR-Cas9-mediated gene targeting and transplantation of modified mouse SSCs ([@dmw017C148]). Figure 2The CRISPR-Cas9 system. The Type II *Streptococcus pyogenes* clustered regulatory interspaced short palindromic repeats-associated protein 9 (CRISPR-Cas9) (SpCas9) system, which is the simplest and most extensively used CRISPR-Cas9 technology, is based on a guide-RNA (gRNA) containing a specific 20 bp sequence to guide the DNA endonuclease Cas9 to a complementary target DNA sequence in the genome where it induces a DNA double-strand break (DSB). The 20-bp target genomic DNA must be upstream of a specific sequence (5′-NGG, where N represents a random nucleotide). The Cas9-induced DSB occurs \~3-bp upstream of the 5′-NGG, and can in theory be induced in any 20-bp genomic DNA sequence flanking 5′-NGG. The Cas9-induced DSB will then be repaired by either homology-directed repair (HDR), which can occur with the presence of DNA repair templates, or by non-homologous end joining (NHEJ). The error-prone NHEJ creates insertions/deletions (indels) around the DSB point. Indels, especially when occurring in early coding exons, can cause loss of gene function (gene knockout) by causing a frame shift that can lead to formation of a pre-mature stop codon. In contrast, HDR uses a template sequence for very precise repair of the DSB. Exogenous DNA repair templates (with the required sequences placed between homology arms) can be provided to the cells together with other components of the CRISPR-Cas9 system to create specific indels or modifications at target genomic loci. Thus, the CRISPR-Cas9 system can be used to insert sequences or correct disease-causing mutations in a very accurate way.

Curing spermatogenic failure by transplantation of genetically modified SSCs {#dmw017s9b}
----------------------------------------------------------------------------

A proportion of infertile men have non-obstructive azoospermia as a result of spermatogenic arrest. However, in 41% of these patients a few germ cells escape the arrest and form elongated spermatids, which can be extracted from testicular tissue by means of TESE and used for fertilization in an ICSI procedure ([@dmw017C143]). When no sperm is found during this procedure, no treatment options are currently available. Fortunately, [@dmw017C80] have shown that spermatogonia from patients suffering from non-obstructive azoospermia due to a maturation arrest are able to proliferate in their long-term culture system in a similar manner as men with obstructive azoospermia. Therefore, SSCs might be used in future SSCT as a valid option to treat these men.

Very recently, [@dmw017C156] employed TALENs to successfully rectify a point mutation in the mouse *c-kit* gene that blocks spermatogonial differentiation, and after correction spermatogenesis could be rescued, for the first time demonstrating that spermatogenic failure-related genetic defects can be corrected by genome editing platforms. Thus, it makes sense that after CRISPR-Cas9-mediated correction of the genetic defects responsible for spermatogenic failure, SSCs from azoospermic men can subsequently be used for SSCT, offering men with spermatogenic failure a patient-tailored treatment option. Besides, in small cohorts of azoospermic men, various single nucleotide polymorphisms (SNPs) associated with arrests during spermatogenesis have been identified ([@dmw017C3]; [@dmw017C132]; [@dmw017C101]; [@dmw017C38]; [@dmw017C51]), forming additional candidate targets for genetic modification of SSCs. A recent article reports the use of CRISPR-Cas9 to interrogate male infertility-related SNPs in mice ([@dmw017C127]). In addition, the recently developed genome-scale CRISPR knockout (GeCKO) enables the targeting of a variety of genes in parallel ([@dmw017C125]; [@dmw017C118]). Because infertility is often not believed to be a monogenic disorder but is rather thought to be caused by a spectrum of genes ([@dmw017C57]), the GeCKO system could serve as a prospective platform for gene therapy of such patients. Hence, when the infertility-causing genetic mutations are known, SSCs could first be isolated from testicular biopsies and propagated *in vitro* to increase their number. Subsequently, the propagated SSCs could be co-transfected with CRISPR-related vectors (to cut DNA) and exogenous DNA repair templates specific for the mutations (to induce homology-directed repair, Fig. [2](#dmw017F2){ref-type="fig"}) in a patient-specific manner. Finally, after selection and whole genome (epi)genetic off-target analysis, the modified SSCs can be autotransplanted into the testis to initiate spermatogenesis and produce corrected sperm.

Preventing diseases in offspring by transplantation of genetically modified SSCs {#dmw017s9c}
--------------------------------------------------------------------------------

Carriers of inherited genetic diseases, albeit often fertile, have to make important decisions when it comes to reproduction. Couples can opt to remain childless to prevent diseases in their children, opt for adoption or resort to a germ cell donor. Alternatively, these couples can attempt to have their own biological children and detect whether their prospective children are carriers of the disease via prenatal testing during pregnancy. In case the fetus is a carrier of the disease, the parents have to make the emotionally laden decision whether to terminate their pregnancy. Couples can also opt for PGD as a preventive measure for the birth of a child with a genetic defect. PGD is well established for monogenic diseases such as cystic fibrosis ([@dmw017C36]), beta thalassemia ([@dmw017C73]) and Huntington's disease ([@dmw017C124]). In PGD, couples undergo IVF treatment in which a single cell is aspirated from each embryo at the 6--8 cell stage to perform subsequent genetic testing for high-risk disease alleles. Only unaffected embryos are transferred to prevent the birth of children with these severe genetic diseases.

Even though PGD provides a solution for couples at risk for transmitting a genetic disease, IVF treatment of the women, including ovarian hyperstimulation, is indispensable in the process of PGD. Moreover, many embryos are created, while only a few will be used to induce pregnancy.

Currently there is no way to prevent genetic diseases in the offspring without creating affected embryos. Nevertheless, if the prospective father is the carrier of a disease allele, the disease-causing mutation can theoretically be corrected in isolated SSCs during *in vitro* culture. Subsequently, transplantation of the modified SSCs would result in genetically normal sperm and therefore prevent transfer of the disease allele to the next generations. Additionally, it would enable male carriers at risk for transmitting genetic diseases to naturally conceive a healthy child without IVF or prenatal genetic testing.

Inspiringly, CRISPR-Cas9 has been shown to successfully repair mutations in disease-causing genes in different species and cell types. In mice, mutations in the *Crygc* gene (which causes cataracts) ([@dmw017C147]), dystrophin gene (which causes Duchenne muscular dystrophy, DMD) ([@dmw017C81]) and a *Fah* mutation in hepatocytes ([@dmw017C155]) have been repaired by the CRISPR-Cas9 system. In human trials, the CRISPR-Cas9 system has been used to precisely correct the hemoglobin beta and dystrophin gene, in β-thalassemia ([@dmw017C152]) and DMD patient-induced pluripotent stem cells ([@dmw017C78]), respectively. Another report describes successful repair of the cystic fibrosis transmembrane conductor receptor locus in cultured intestinal stem cells from patients with cystic fibrosis ([@dmw017C123]). These reports raise the possibility that CRISPR-Cas9 could be used to repair inheritable mutations through the germline.

Interestingly, a recent article reports successful genome editing of mouse SSCs with the CRISPR-Cas9 system ([@dmw017C148]). Transplantation of the genetically modified SSCs led to fertile offspring, in which a *Crygc* mutation causing cataracts was corrected. To our knowledge, this is the first report that describes CRISPR-Cas9-mediated genome editing in SSCs in combination with SSCT, thereby preventing diseases in the offspring. Furthermore, as the transplanted SSCs were the cell lines derived from isolated and corrected single cells, this method can generate healthy descendants at 100% efficiency, thereby averting the problem of mosaicism. In addition to this pioneering work, two other recent articles also provide the proof of concept by showing CRISPR-Cas9 and SSCT-induced germline transmission in rodents ([@dmw017C11]; [@dmw017C119]). Hence, SSCT and the CRISPR-Cas9 system can be well combined in the future to prevent the transmission of inheritable diseases to the offspring.

Epigenetic editing of SSCs {#dmw017s9d}
--------------------------

Mechanisms that underlie cellular functioning are orchestrated by different layers of transcriptional regulation. Apart from genetic factors, epigenetic regulation is key for the proper functioning of a cell. Epigenetic traits are defined ([@dmw017C6]) as 'heritable phenotypes resulting from changes in a chromosome without alterations in the DNA sequence', mediated by several factors such as DNA methylation, histone modifications and higher order chromatin structuring. Disruption of epigenetic regulation has been shown in an array of complex diseases, including cancer, diabetes and cardiovascular diseases (reviewed in [@dmw017C83]; [@dmw017C98]; [@dmw017C15]). Thus, in theory, epigenetic editing may be a valid alternative for genetic repair to modify aberrant gene expression in SSCs from those at risk of transmitting diseases to their own biological children.

The core of currently described epigenetic editing approaches is the fusion of an epigenetic modulatory enzyme to a protein with a DNA binding domain in order to affect gene expression and modulate local parameters, such as cytosine methylation and demethylation or histone modification once the enzymatic construct is in place. This powerful approach has been used to silence and/or activate specific DNA sequences by altering epigenetic parameters of target genes (reviewed in [@dmw017C17]; [@dmw017C21]). For example, a recent study describes the guidance of the Ten-Eleven Translocation 2 DNA demethylation enzyme to the promoter region of the intercellular adhesion molecule 1 gene, causing local demethylation and reactivation of the gene where it was normally silenced ([@dmw017C12]). Another group has reported the development of a programmable molecular construct consisting of a nuclease-deactivated Cas9 (dCas9) protein fused to the catalytic core of the acetyltransferase p300, which can be used to modulate histone acetylation of any Cas9-targetable genomic location ([@dmw017C47]). One might imagine that epigenetic editing techniques might allow correction of the transcriptional regulation of pivotal genes in various biological processes, including germ cell development. Epigenetics have been shown to play a key role in normal germ cell development ([@dmw017C25]; [@dmw017C2]; [@dmw017C35]), and allele-specific DNA methylation was altered in semen from men that suffer from spermatogenic failure ([@dmw017C107]; [@dmw017C67]; [@dmw017C23]; [@dmw017C110]; [@dmw017C136]). Local correction of abnormal DNA methylation or histone modification of target genes in infertile men might improve the spermatogenic potential.

In theory, SSCT of epigenetically modified SSCs may also be applicable for inherited epigenetic diseases. Epidemiological data point to human transgenerational epigenetic inheritance, including the Dutch Famine Birth Cohort Study ([@dmw017C82]; [@dmw017C39]; [@dmw017C100]; [@dmw017C141]) and the Swedish Overkalix population ([@dmw017C102]). Additionally, a few (case) studies describe inheritance of a disease-associated epimutation of a specific locus, such as the SNURF-SNRPN locus in Prader--Willi and Angelman syndrome ([@dmw017C10]) and the cancer predisposing gene MLH1 ([@dmw017C130]). However, one must realize that the epigenome is reset in an extensive way during early embryonic development ([@dmw017C16]; [@dmw017C145]). Even though some inherited epigenetic marks seem to escape epigenetic reprogramming, it remains unclear whether epigenetic germline editing combined with SSCT may benefit patients in the future. Therefore, more research is needed before SSCT can be applied to cure heritable epigenetic diseases.

Clinical and technical hurdles and drawbacks {#dmw017s10}
============================================

The field of SSCT is uprising, and a variety of patient groups may benefit from this therapy in the future. However, some hurdles still need to be overcome prior to its clinical implementation. For one thing, safety of the patient and his offspring is of major concern ([@dmw017C129]). Human SSCs may change (epi)genetically when exposed to an *in vitro* environment. Yet, there is evidence of genetic stability of cultured human SSCs ([@dmw017C91]). DNA methylation of maternal and paternal imprinted genes in uncultured murine SSCs did not alter after transplantation ([@dmw017C31]; [@dmw017C146]), whereas cultured human SSCs showed changes in DNA methylation in some selected regions of maternal and paternal imprinted genes ([@dmw017C91]). Conclusively, although the published data suggest that SSCT may be safe for the clinic, more (pre)clinical studies are needed in this field to ensure safety for patients, as well as for their offspring.

Another challenge in cancer patients is that primary testicular cultures may be contaminated with lingering cancer cells from leukemic or metastasized patients. While some researchers were unable to successfully sort out cancer cells ([@dmw017C27]), others succeeded in removing leukemic cells from testicular cultures ([@dmw017C115]) or from cell suspensions ([@dmw017C44]).

In comparison, the clinical implementation of genomically modified SSCT is even more challenging. Aside from the potential risks accompanying conventional SSCT, we currently do not know whether genomic manipulation of SSCs harbors any extra risks for the patient or his offspring. In addition, a major clinical drawback of germline therapy in fertile carriers of diseases remains that the patients have to undergo local irradiation to deplete the testis of endogenous mutated spermatogonia before SSCT. Otherwise, the testis of the recipient father would produce two populations of sperm cells: those that arise from endogenous SSCs carrying the disease-causing mutation as well as those from the corrected SSCs introduced by transplantation. As a consequence, the semen of the father would contain a mixed population of spermatozoa and children conceived by natural conception could be derived from either a corrected or endogenous sperm cell. Although local irradiation has been demonstrated to be an effective measure to deplete the testis of germ cells in animal studies ([@dmw017C161]; [@dmw017C46]), it can have a deleterious influence on outgrowth of seminiferous tubules, especially in prepubertal testes ([@dmw017C55]). Besides, it may cause damages to surrounding organs and cells. Moreover, some endogenous spermatogonia might survive the irradiation and are still capable of developing into spermatids, thereby risking the transfer of the genomic aberrations. In this sense, the development of alternatives to exclude endogenous SSCs is needed to better strike the balance between the benefits of SSCT and the potential risks of the required total depletion of endogenous spermatogenesis.

In terms of genomic manipulation, some technical problems remain to be addressed. First, the CRISPR-Cas9 components need to be delivered into cells. The way in which the Cas9 nuclease is introduced (viral or non-viral) has significant clinical implications (Table [1](#dmw017TB1){ref-type="table"}). In case of viral transduction, CRISPR-sequences, and possibly even residual viral sequences, integrate into the genome of the patient. This raises serious safety concerns and is not suitable for clinical application. However, non-viral delivery methods often fall short, as they can be inefficient in gene delivery (e.g. liposome-mediated transfection), are laborious (e.g. microinjection) or lead to significant cell mortality (e.g. electroporation). While SSCs have been demonstrated to be refractory to most non-viral transfection approaches ([@dmw017C61]), novel electroporation devices that are currently being used in some laboratories may be the option to transfect SSCs with adequate efficiency ([@dmw017C159]; [@dmw017C22]; [@dmw017C148]; [@dmw017C11]; [@dmw017C119]). Alternatively, transfection of the mRNA instead of the corresponding DNA vectors has been shown to be more efficient for genome editing ([@dmw017C22]). Also the recently developed novel method regarding direct intracellular delivery of proteins might serve as another option for gene targeting ([@dmw017C14]).

In spite of the developments, one needs to realize that SSCT in combination with genomic editing to cure or prevent diseases is only feasible when the genetic mutation is known. Unfortunately, the genetic etiology remains elusive in many cases. More research on the identification of genomic mutations that cause subfertility is necessary in this respect ([@dmw017C142]; [@dmw017C134]; [@dmw017C70]). A recent article describes that CRISPR-Cas9 was exploited to successfully eradicate porcine endogenous retroviruses with the copy number as high as 62 in a porcine cell line ([@dmw017C154]), showing the robustness and versatility of CRISPR. However, various genetic diseases, including subfertility, are believed to be caused by an array of genes ([@dmw017C57]), which renders genetic correction substantially more difficult as it would require simultaneous targeting of various loci. A previous report shows that a maximum of five genes could be simultaneously disrupted by microinjection of CRISPR components into mouse ESCs ([@dmw017C144]). At present, the novel GeCKO system seems to be the only possible approach to targeting a wide array of genes in parallel. Nevertheless, GeCKO, which requires lentiviral transduction and subsequent integration of CRISPR components into the genome, is considered unsafe for clinical application at the moment. We still need to await further development in this regard before we can target a variety of genes in parallel safely for clinical purposes.

Another important issue is the potential off-target alterations induced by the CRISPR-Cas9 system. Recent studies have revealed that the 20-bp gRNA-DNA hybrid (Fig. [2](#dmw017F2){ref-type="fig"}) has the potential to tolerate 1--3 or even more sequence mismatches ([@dmw017C24]; [@dmw017C84]; [@dmw017C117]). As a consequence, normal genes containing high homology to the target sequence might also be targeted. Reassuringly, whole genome sequencing of the CRISPR-Cas9-modified SSCs showed no apparent off-target mutations ([@dmw017C148]). Moreover, novel versions of CRISPR with enhanced specificity but without the sacrifice of on-target activity have been developed recently ([@dmw017C128]; [@dmw017C68]), which will further facilitate its broad applications in the clinic.

Also, the targeting spectrum of the CRISPR-Cas9 system needs to be expanded. The requirement of a specific sequence (e.g. 5′-NGG for type II SpCas9, Fig. [2](#dmw017F2){ref-type="fig"}) following the target is a principal constraint. While 5′-NGG occurs quite frequently in the human genome, further extensions of the targeting range by development of other types of CRISPR that recognize distinct sequences downstream of the targeting site ([@dmw017C160]; [@dmw017C93]) would give broader options for genome editing.

Ethical issues {#dmw017s11}
==============

As genomic modification of SSCs leads to germline transmission of the modified trait to the next generation, elaborate ethical reflection and an intensive societal debate on the acceptability of a clinical application of germline gene editing should precede the actual clinical application of modified SSCs. Recently two groups employed the CRISPR-Cas9 system to achieve genome editing in human tripronuclear zygotes ([@dmw017C79]; [@dmw017C62]). Although the zygotes used were unable to develop into viable embryos, these reports still initiated major debates. Some people propose a complete ban on germline genomic editing ([@dmw017C76]), while others request a moratorium on the clinical application of germline editing but suggest permission for research in this field ([@dmw017C5]). To date, multiple articles have been published to broaden the discussion ([@dmw017C52]; [@dmw017C87]; [@dmw017C106]; [@dmw017C108]; [@dmw017C140]). We strongly support the establishment of a societal platform including molecular and (stem) cell biologists, medical professionals, ethicists, politicians, citizens and most importantly patients, to discuss under which circumstances and to what extent germline modification should be allowed.

Concluding remarks {#dmw017s12}
==================

In this review, we explore different patient groups that may benefit from SSCT with or without genomic editing. We conclude that the clinical implementation of SSCT can potentially reach far beyond fertility preservation in childhood cancer patients. Conventional SSCT could help adult cancer patients preserve their fertility, while fertility may also be enhanced in oligozoospermic or azoospermic patients using this technology. Successful genomic modification of SSCs by the novel CRISPR-Cas9 system in culture could repair detrimental mutations, thereby treating patients with non-obstructive azoospermia and carriers of diseases in the future.

The safety of the patient and the following generations is of paramount importance. From our perspective, by no means should these techniques be employed in the clinic until safety and efficiency has been demonstrated empirically. Therefore, more fundamental research remains to be conducted. In addition, a societal and ethical debate should precede the use of modified SSCs in a future clinical application of SSCT.

Nonetheless, SSCT, with or without genome editing, is a potential powerful platform that potentially can be employed to cure infertility or even inheritable mutations in various patient groups. Research in this field is thriving, and a revolution might be visible at the horizon.
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